title: Elevated BUBR1 expression is associated with poor survival in early breast cancer patients: 15-year follow-up analysis.
abstract: BUBR1 (budding uninhibited by benzimidazole-related 1) represents the component of a controlling complex in mitosis. Defects in mitotic control complex result in chromosomal instability and, as a result, disturb the mitotic process. This study was aimed at examining the prognostic value linked to the expression of BUBR1 in a group of patients with breast cancer. We analyzed the expression of BUBR1 in 98 stage II breast cancer patients with a median follow-up of 15 years. Immunohistochemical reactions were performed using monoclonal antibodies against BUBR1. We also studied the prognostic value of BUBR1 mRNA expression using the Kaplan-Meier (KM) plotter, which assessed the effect of 22,277 genes on survival in 2422 breast cancer patients. A background database was established using gene expression data and survival information on 2422 patients downloaded from the Gene Expression Omnibus (GEO; Affymetrix HGU133A and HGU133+2 microarrays). The median relapse-free survival was 6.43 years. Univariate and multivariate analyses showed that higher expression of BUBR1 was typical for cases of shorter overall survival, disease-free time, and disease-specific survival. KM plotter analysis showed that elevated BUBR1 mRNA expression had a negative impact on patients' relapse-free, distant metastases-free, and overall survival. Elevated BUBR1 expression was associated with poor survival in early stage breast cancer patients.
authors: Lower Silesian Centre of Oncology, Wrocław, Poland.
authors: Adam
authors: A
authors: Maciejczyk
authors: Jolanta
authors: J
authors: Szelachowska
authors: Bogdan
authors: B
authors: Czapiga
authors: Rafał
authors: R
authors: Matkowski
authors: Agnieszka
authors: A
authors: Hałoń
authors: Balázs
authors: B
authors: Györffy
authors: Paweł
authors: P
authors: Surowiak
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology* / Q000628:therapy; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009367:Neoplasm Staging; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D016019:Survival Analysis
chemical_list: C584277:BUB1 protein, human; C090464:Bub1 spindle checkpoint protein; D017346:Protein Serine-Threonine Kinases
references: Cancer Res. 2002 Jan 1;62(1):13-7
references: 11782350
references: Anticancer Res. 2008 Jan-Feb;28(1A):139-44
references: 18383837
references: Trends Biochem Sci. 2011 Mar;36(3):141-50
references: 20888775
references: Cancer Res. 2007 Nov 1;67(21):10103-5
references: 17974949
references: Surg Gynecol Obstet. 1965 Dec;121(6):1221-30
references: 5851617
references: Mol Pharmacol. 2008 Feb;73(2):419-30
references: 17991869
references: Histopathology. 1991 Nov;19(5):403-10
references: 1757079
references: Neoplasia. 2008 Jul;10(7):643-52
references: 18592005
references: Pathologe. 1987 May;8(3):138-40
references: 3303008
references: Patholog Res Int. 2011;2011:489064
references: 21785684
references: Breast Cancer Res Treat. 2010 Oct;123(3):725-31
references: 20020197
references: Histol Histopathol. 2011 Jun;26(6):761-8
references: 21472690
references: Br J Cancer. 1957 Sep;11(3):359-77
references: 13499785
references: Br J Cancer. 2009 Aug 4;101(3):504-10
references: 19603021
references: Ann Oncol. 2009 Aug;20(8):1319-29
references: 19535820
references: Cell Cycle. 2008 Jun 15;7(12):1763-8
references: 18594200
references: N Engl J Med. 2010 Dec 30;363(27):2628-37
references: 21190457
references: Cancer. 1975 Mar;35(3):710-3
references: 1111938
references: Carcinogenesis. 2009 Sep;30(9):1469-74
references: 19372138